Clinical Trials Browser

Interventional × Piebaldism × ponatinib × Clear all

NCT02272998 2025-03-24

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Phase 2 Completed

22 enrolled 13 charts

Neoplasms, Piebaldism